Melanoma Clinical Trials in Seattle

Showing 101-120 of 124 trials

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

NCT00871481

This phase I/II trial is studying the side effects of giving laboratory-treated T cells and ipilimumab together to see how well they work in treating patients with metastatic melanoma. Treating a patient's T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving laboratory-treated T cells together with ipilimumab may kill more tumor cells

Recurrent MelanomaStage IV Melanoma

Fred Hutchinson Cancer Center10 participantsStarted Feb 2009

Seattle, Washington, United States

TERMINATEDPhase 2< 1 mile

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

NCT01120275

This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with stage IV melanoma. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Acral Lentiginous Malignant MelanomaLentigo Maligna Malignant MelanomaNodular Malignant Melanoma+4 more

National Cancer Institute (NCI)36 participantsStarted Oct 2010

Mobile, Alabama, United States • Fairbanks, Alaska, United States • Tucson, Arizona, United States +175 more locations

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Melanoma Trials in Other Cities

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Study of CP-675,206 in Refractory Melanoma

SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma

Phase II Trial of Allovectin-7® for Metastatic Melanoma

Biological Therapy in Treating Patients With Metastatic Melanoma

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Phase II, 2nd Line Melanoma - RAND Monotherapy

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Other Conditions in Seattle